Pharmaceutical Business review

Lilly’s cancer drug receives CHMP’s positive opinion

Alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.